---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Sodium-Glucose cotransporter-2 inhibitors"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Sodium-Glucose cotransporter-2 inhibitors. Topics: SGLT2 inhibitor recommendations: KDIGO 2024 CKD guideline, Dapagliflozin in biopsy-confirmed FSGS: DAPA-CKD prespecified analysis, and No SGLT2 inhibitor data specific to APOL1 kidney disease. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/sodium-glucose-cotransporter-2-inhibitors"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Sodium-Glucose cotransporter-2 inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Sodium-Glucose Cotransporter-2 Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### SGLT2 inhibitor recommendations: KDIGO 2024 CKD guideline

> “However, in the present guideline, we offer a more general 1A recommendation for adults with CKD.”
> “Recommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):”
> “Recommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).”
> “Practice Point 3.7.3: SGLT2i initiation or use does not necessitate alteration of frequency of CKD monitoring and the reversible decrease in eGFR on initiation is generally not an indication to discontinue therapy.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### Dapagliflozin in biopsy-confirmed FSGS: DAPA-CKD prespecified analysis

> “Of 104 participants with biopsy-confirmed FSGS, 45 were randomized to dapagliflozin and 59 to placebo.”
> “The primary outcome occurred in 4 (8.9%) and 7 (11.9%) participants randomized to dapagliflozin and placebo, respectively [hazard ratio 0.62, 95% confidence interval (95% CI) 0.17, 2.17].”
> “Thereafter, mean rates of chronic eGFR decline with dapagliflozin and placebo were −1.9 (−3.0, −0.9) and −4.0 (−4.9, −3.0) mL/min/1.73 m2/year, respectively (difference 2.0, 95% CI 0.6 to 3.5, mL/min/1.73 m2/year).”
> “With respect to limitations, the DAPA-CKD study was not specifically designed to test our hypothesis in patients with FSGS, and the relatively small sample size of this subgroup limited the precision of estimates of treatment effects on the study endpoints.”

Source: [Wheeler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9395378/)

<a id="topic-2.2.2.1.2-3"></a>

### No SGLT2 inhibitor data specific to APOL1 kidney disease

> “Of note, much of the data on CKD progression due to APOL1 variants came before the widespread use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dual angiotensin and endothelin receptor antagonists, and it is unclear whether such therapies influence disease development or progression.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “In the current review, we highlight the potential reasons for exploring the use of SGLT2i in APOL1-KD. Future studies are warranted to explore if SGLT2i use can provide protection in APOL1-KD.”

Source: [Afsar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40038200/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
